News Press Releases

Reven received approval for our Family Two 1st Divisional Patent.

Reven filed a Family One continuation patent.

Reven submits divisional patents in Canada and Mexico.

Reven receives approval in Canada for our Family Two Patent.

Reven selected an Australian Contract Manufacturing Organization (CMO) to supply drug product for Phase I Clinical Trial

Reven selected an Australian Contract Manufacturing Organization (CMO) to supply drug product for Phase I Clinical Trial.

Canadian Intellectual Property Office approved our Family Two patent in Canada

Canadian Intellectual Property Office approved our Family Two patent in Canada.

The US Patent and Trademark Office (USPTO) allowed Reven RJX Family One Child Patent, application # 14,550,677. This is our “method of treating” patent.

Joy Powell hired as Reven’s Senior Project Manager overseeing analytical and bioanalytical work.

Reven selected Linear Clinical Research as the Phase I research site in Australia.

The US Patent and Trademark Office (USPTO) allowed Reven RJX Family One Child Patent, application # 14,550,677. This is our “method of treating” patent.

Reven selected Linear Clinical Research as the Phase I research site in Australia.

Reven initiates Phase I Clinical Trial in Australia to run in conjunction with planned Phase I/IIa in the USA

Reven initiates Phase I Clinical Trial in Australia to run in conjunction with planned Phase I/IIa in the USA.